Table 2. Patients' demographics according to BiotHER status.

	BiotHER−	BiotHER+
Characteristic	N=27	N=27
Median age in years (range)	55 (35–75)	50 (36–76)
Median DFS in months (range)	21 (0–134)	24 (0–119)
Median number of metastatic sites (range)	2 (1–4)	2 (1–3)
Patients with single metastatic sites	8 (30%)	11 (41%)
Visceral involvement (liver+lung)	19 (70%)	22 (81%)
Liver involvement	14 (52%)	15 (56%)
Prior chemotherapy for metastatic disease	18 (67%)	23 (85%)
Prior adjuvant/neoadjuvant chemotherapy	15 (56%)	18 (67%)
Prior exposure to antracyclines	18 (67%)	16 (59%)

N=number; DFS=disease-free survival from initial diagnosis to metastatic progression.